Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
OKTA heads into October with a striking gap between its price chart and its short book: the stock is up 28% over the past month, yet short sellers have added meaningfully to their positions over the same period.
The positioning picture is less alarming than it first appears, but it is worth unpacking. Short interest has climbed 30% over the past month to 4.95% of the free float, and rose a further 3.7% this week alone. That is a meaningful rebuild, though the absolute level remains below the threshold where squeeze dynamics typically become relevant. The borrow market tells a similar story of low tension: availability is extraordinarily loose at 2,625% of short interest, meaning there are roughly 26 shares available to lend for every one already borrowed. Cost to borrow has eased to 0.33% this week, down 14% on the week, though it is up modestly over the month. Shorts are not finding it hard to put on positions. Options traders have actually grown less defensive as the stock rallied. The put/call ratio sits at 1.04, below its 20-day average of 1.12, and roughly 0.7 standard deviations under that mean. This time last month, the PCR was running well above 1.3. The combination of shorts rebuilding while options hedging retreats is an unusual split: one camp is leaning bearish, the other is easing off protection.
The Street is firmly in the bull camp. After Okta's August earnings print, which sent the stock up 32% in a single session and 25% over the following five days, target prices were reset aggressively. Morgan Stanley raised its target to $245 from $200 last week, maintaining Overweight. Scotiabank went to $245 from $190. Macquarie, Truist, Stephens, BMO, and Baird all raised targets into the $230 to $240 range in a cluster around September 25. Bank of America, which remains cautious at Neutral, lifted its target to $220 from $200. The consensus mean target is $212, which is now slightly below the current price of $218. Amerx initiated coverage at Hold this week. At a price/earnings multiple of 51x and EV/EBITDA of 37.5x, valuation is not stretched by recent norms but leaves limited room for disappointment. The P/B has expanded more than one full turn over the past month, reflecting how quickly the market has re-rated the name. The ORTEX short score of 37.9 places it roughly in the middle of the range, consistent with a stock where short pressure is present but not dominant.
The bull case centres on identity's growing role in AI security, Okta's cross-sell opportunity into IGA, PAM, ITDR, and agentic identity, and the momentum evident in the August print: cRPO of $2.59 billion, up 14% year-on-year, with a non-GAAP operating margin of 28.5%. Bears focus on workforce identity seat pressure, the ongoing challenge of consolidating two standalone CIAM platforms following the Auth0 acquisition, and the risk of IT budget softening hitting CIAM expansion before PAM and governance upsells can compensate. Competition in agentic identity is also intensifying. The ORTEX alt data layer flags that retail attention is running at a two-standard-deviation spike above Okta's own 90-day average based on Wikipedia page views, consistent with the post-earnings surge in profile, though this dataset has not been measured to lead reported financials.
The most noteworthy ownership development is on the insider side. CEO Todd McKinnon sold approximately $10.6 million of stock on September 22, spread across multiple tranches at prices between $189 and $198. All transactions were conducted under a pre-arranged 10b5-1 plan, which reduces the signal value considerably since the trades were scheduled in advance rather than being a discretionary read on near-term prospects. On the institutional side, FMR LLC added 3 million shares and now holds 10.8% of shares. BlackRock added 714,000 shares to reach 10.7%. The Vanguard group has restructured its holdings across two separate vehicles, each now filing independently, but the aggregate Vanguard exposure appears broadly unchanged. No 13D activists are on the register.
The next earnings event is December 2. Between now and then, the question is whether short sellers who rebuilt positions into the post-earnings rally will unwind or press further, and whether the analyst community will need to revise targets again given that consensus has already been outrun by the stock price.
See the live data behind this article on ORTEX.
Open OKTA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
